Farglitazar
Chemical compound
- N/A
- none
- Development discontinued
- N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
- 196808-45-4 Y
- 170364
- 2672
- 148961 Y
- 3433GY7132
- D04132
- ChEMBL107367 Y
- DTXSID1047310
- Interactive image
- O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
InChI
- InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 N
- Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N N
Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.[1] After reaching phase III for type 2 diabetes, further development was discontinued.[2][3]
References
- ^ McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. (April 2010). "Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection". Gastroenterology. 138 (4): 1365–73, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
- ^ "Farglitazar". Adis Insight. Springer Nature Switzerland AG.
- ^ "Farglitazar". pharmacodia.com.
- v
- t
- e
PPARTooltip Peroxisome proliferator-activated receptor modulators
- Agonists: 15-HETE
- 15-HpETE
- Aleglitazar
- Aluminium clofibrate
- Arachidonic acid
- Bezafibrate
- Chiglitazar
- Clofibrate
- CP-775146
- Daidzein
- DHEA (prasterone) (in rodents)
- Elafibranor
- Etomoxir
- Fenofibrate
- Genistein
- Gemfibrozil
- GW-7647
- Lanifibranor
- Leukotriene B4
- LG-101506
- LG-100754
- Lobeglitazone
- Muraglitazar
- Oleylethanolamide
- Palmitoylethanolamide
- Pemafibrate
- Perfluorononanoic acid
- Perfluorooctanoic acid
- Pioglitazone
- Saroglitazar
- Sodelglitazar
- Tesaglitazar
- Tetradecylthioacetic acid
- Troglitazone
- WY-14643
- Antagonists: GW-6471
- MK-886
- Agonists: 15-HETE
- 15-HpETE
- Arachidonic acid
- Bezafibrate
- Daidzein
- Elafibranor
- Fonadelpar
- Genistein
- GW-0742
- GW-501516
- L-165,041
- Lanifibranor
- LG-101506
- Seladelpar
- Sodelglitazar
- Tetradecylthioacetic acid
- Antagonists: FH-535
- GSK-0660
- GSK-3787
- Agonists: 5-Oxo-ETE
- 5-Oxo-15-hydroxy-ETE
- 15-Deoxy-Δ12,14-prostaglandin J2
- 15-HETE
- 15-HpETE
- Aleglitazar
- Arachidonic acid
- Balaglitazone
- Berberine
- Bezafibrate
- Cannabidiol
- Cevoglitazar
- Chiglitazar
- Ciglitazone
- Daidzein
- Darglitazone
- Edaglitazone
- Efatutazone
- Englitazone
- Etalocib
- Farglitazar
- Genistein
- GW-1929
- Ibuprofen
- Imiglitazar
- Indeglitazar
- Lanifibranor
- LG-100268
- LG-100754
- LG-101506
- Lobeglitazone
- Muraglitazar (muroglitazar)
- nTZDpa
- Naveglitazar
- Netoglitazone
- Oxeglitazar
- Peliglitazar
- Pemaglitazar
- Perfluorononanoic acid
- Pioglitazone
- Prostaglandin J2
- Ragaglitazar
- Reglitazar
- Rivoglitazone
- Rosiglitazone
- RS5444
- Saroglitazar
- Sipoglitazar
- Sodelglitazar
- Telmisartan
- Tesaglitazar
- Troglitazone
- Antagonists: FH-535
- GW-9662
- SR-202
- T-0070907
- Unknown: SR-1664
- Agonists: Ciprofibrate
- Clinofibrate
- Clofibride
- Englitazone
- Etofibrate
- Farglitazar
- Netoglitazone
- Ronifibrate
- Rivoglitazone
- Simfibrate
- See also
- Receptor/signaling modulators
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e